IRVINE, Calif., Nov. 11, 2015 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ:ELOS), a leading global aesthetic device company, announced today that it has enhanced its North American leadership team with the appointment of Jeff Nardoci as President of its North America Body Shaping Group. In this position, Mr. Nardoci will be responsible for the development and execution of the Company's growth strategies for UltraShape and VelaShape. He will report to Bill Griffing, CEO of Syneron Candela North America.
Amit Meridor, Chief Executive Officer of Syneron Medical, said, "Since joining Syneron in July, Jeff has demonstrated strong leadership skills and contributed significantly to our North America team. Combined with his strong track record of driving growth strategies in previous positions, this gives us confidence that he will have a significant impact on our execution in the body shaping market. His main focus will be the ongoing launch of UltraShape, driving our strategy for gaining market share and partnering with customers to increase system utilization. He has relevant experience leading a recurring revenue business model in aesthetics, including working closely with customers with an integrated team approach to provide effective and meaningful support."
Mr. Nardoci said, "UltraShape and VelaShape are uniquely positioned as highly-effective, patient- and practice-friendly devices with complementary body shaping applications. They address a large and growing market opportunity and we are very well positioned given the strength of our technology, strong customer relationships, and high patient and practice satisfaction with our devices. Our products are uniquely positioned to provide fast, comfortable and customizable body shaping treatments. The group has achieved strong results to-date and we will continue to invest in our sales and marketing programs to capture a greater share of the body shaping market. In my time at Syneron I have been impressed with the Body Shaping Group and I am excited by our tremendous potential to drive growth as we continue to execute on the launch of UltraShape."
Mr. Nardoci joined Syneron's North American team in July 2015 as Senior Vice President, Commercial and Customer Strategy with responsibility for the development and implementation of strategies and programs to drive growth and improve efficiencies of the North American Body Shaping and Aesthetics Groups. Prior to joining Syneron, Mr. Nardoci served as Senior Vice President, Chief Strategy & Marketing Officer at Banner Health. In this position, he was responsible for the development of a long range strategic plan and annual operating plan supporting a $6 billion health care system. Prior to Banner, he held senior roles at Solta Medical, Bausch & Lomb, and Nabisco Foods Group. Mr. Nardoci received a B.A. in Economics from Fairleigh Dickinson University.
About Syneron Candela:
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch, and has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay, Profound and elos Plus.
Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Candela are located in Israel. Syneron Candela also has R&D and manufacturing operations in the U.S. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
For additional information, please visit http://www.syneron-candela.com.
SOURCE Syneron Medical Ltd.